Publications by authors named "Josue Amici Heradi"
Article Synopsis
- Late-stage human African trypanosomiasis (g-HAT), caused by Trypanosoma brucei gambiense, has limited treatment options, typically requiring hospital-administered combination therapy, which is impractical for patients in remote areas.
- This study evaluated the safety and efficacy of an oral medication, fexinidazole, compared to the standard nifurtimox and eflornithine combination therapy in patients with late-stage g-HAT in the Democratic Republic of the Congo and Central African Republic.
- The trial was a randomized, open-label study with a primary endpoint measuring treatment success at 18 months, involving monitoring for both efficacy and safety of the medications administered.
Background: Existing diagnostic and treatment tools for human African trypanosomiasis (HAT) are limited. The recent development of nifurtimox-eflornithine combination therapy (NECT) has brought new hopes for patients in the second stage. While NECT has been rolled out in most endemic countries, safety data are scarce and derive only from clinical trials.
View Article and Find Full Text PDF